Alyeska Investment Group
PTLA

Alyeska Investment Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Alyeska Investment Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,600
Closed -$565K – 547
2017
Q4 		$565K Hold
11,600
– – ﹤0.01% 406
2017
Q3 		$627K Buy
+11,600
New +$681K ﹤0.01% 435

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Alyeska Investment Group's PTLA Position: Q1 2018 in Review

Alyeska Investment Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2018, closing a stake of 11,600 shares — an estimated $565K sold.

Alyeska Investment Group first reported a position in PTLA in Q3 2017 and held it in 2 quarters. The position peaked at $627K in Q3 2017. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2018.

  • Alyeska Investment Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 11,600 Portola Pharmaceuticals, Inc. shares in Q1 2018, an estimated $565K.
  • Alyeska Investment Group first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Alyeska Investment Group's Portola Pharmaceuticals, Inc. position peaked at $627K in Q3 2017.
  • 180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2018.

Based on Alyeska Investment Group's 13F filing for Q1 2018, filed 15 May 2018.